Omrix Bio higher on news of FDA approval for blood-clotting drug
Shares of Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI) are rising following news after the start of trading that the U.S. Food and Drug Administration approved the company’s drug against minor bleeding.
Evithrom is the first blood-clotting protein to gain approval since 1954 and is the only product currently licensed, the agency said in a statement this morning. It is intended to stop oozing and minor bleeding from capillaries and small veins when standard surgical techniques are ineffective or not practical.
The New York-based company had not released a statement as of mid-afternoon.
At 3:30 p.m. ET shares had added $4.41, or 15%, to $33.48.
